Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-220-1 | CAS number: 68413-48-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08 February 2017 to 29 March 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Dibutyl [[bis[(2-ethylhexyl)oxy]phosphinothioyl]thio]succinate
- EC Number:
- 270-220-1
- EC Name:
- Dibutyl [[bis[(2-ethylhexyl)oxy]phosphinothioyl]thio]succinate
- Cas Number:
- 68413-48-9
- Molecular formula:
- C28H55O6PS2
- IUPAC Name:
- 1,4-dibutyl 2-({bis[(2-ethylhexyl)oxy](sulfanylidene)-λ⁵-phosphanyl}sulfanyl)butanedioate
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- CAS RN 68413-48-9
Physical Description: Pale yellow, clear liquid
Purity: 84%
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: approximately 51 days old
- Weight at study initiation: Males: 293 to 415g; females: 210 to 286g
- Housing: 2–3 rats/cage by sex in solid-bottom cages with bedding material
- Diet: certified feed (PMI Nutrition International, LLC Certified Rodent LabDiet® 5002)
- Water: Reverse osmosis-purified (on-site) drinking water
- Fasting: All males and females (including those not selected for clinical pathology evaluation) were fasted prior to clinical pathology blood collection when food, but not water, was withheld
- Acclimation period: 22 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-26
- Humidity (%): 30-70
- Air changes (per hr): minimum of 10
- Photoperiod: 12-hour light/12-hour dark
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- - PREPARATION OF DOSING SOLUTIONS:
The test substance formulations were prepared in corn oil approximately weekly as single formulations for each dosage level, divided into aliquots for daily dispensation, and stored refrigerated (2ºC to 8ºC), protected from light. The test substance formulations were stirred continuously throughout the preparation, sampling, and dose administration procedures. - Details on mating procedure:
- Males and females were paired on a 1:1 basis within each treatment group following 14 days of treatment and were cohabitated in a solid-bottom cage containing bedding material until positive evidence of mating was confirmed by the presence of a vaginal copulatory plug or the presence of sperm following vaginal lavage. Each mating pair was examined daily. The day when evidence of mating was identified was termed Gestation Day 0 and the animals were separated.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dosing formulations prepared at nominal test substance concentrations of 20, 60, and 200 mg/mL were analyzed using a validated high performance liquid chromatography (HPLC) method, using ultraviolet (UV) absorbance detection at a wavelength of 260 nm.
The results met the protocol-specified acceptance criteria for concentration acceptability for uniform solution formulations. No test substance was detected in the analyzed vehicle. - Duration of treatment / exposure:
- Males were dosed throughout the mating period through 1 day prior to euthanasia for a total of 28 doses.
Females received 14 daily doses prior to pairing and were dosed through Lactation Day 13 for a total of 49-53 doses. - Frequency of treatment:
- Once daily
- Details on study schedule:
- 09 February 2017: Experimental starting date (animal receipt)
03 March 2017: Experimental start date (initiation of test substance administration)
03 March to 30 March 2017: Test substance administration (males)
03 March to 24 April 2017: Test substance administration (females)
16 March to 20 March 2017: Mating period
31 March 2017: Male necropsy
25 April 2017: Last Lactation Day 14 necropsy
20 March 2018: Experimental termination/completion date (signed pathology report)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dosage levels of 100, 300 and 1000 mg/kg bw/day were selected based on the results of a previous 14-day range-finding study. The test substance was administered orally by gavage once daily to 3 groups of Crl:CD(SD) rats, each group consisting of 10 males and 10 females. Dosage levels of 100, 300 and 1000 mg/kg bw/day. A concurrent vehicle control group of 10 rats/sec received the vehicle on the same regimen. The dose volume was 5 mL/kg for all groups. Males and females were approximately 10 weeks of age at the beginning of test substance/vehicle administration. Males received 14 daily doses prior to mating and were dosed throughout the mating period until 1 day prior to necropsy for a total of 28 doses. Females received 14 daily doses prior to mating and were dosed through Lactation Day 13 for a total of 49-53 doses.
Examinations
- Parental animals: Observations and examinations:
- Clinical Observations and Survival
All animals were observed twice daily for moribundity and mortality. Clinical observations were recorded daily and detailed physical examinations were conducted weekly. Observations for signs of toxicity were recorded approximately 1.5 hours after dose administration. Social groups were observed at appropriate intervals for findings that could not be attributed to a single animal.
Body Weights
Individual body weights were recorded weekly throughout the study for males, and weekly until evidence of copulation was observed for females. Once evidence of mating was observed, female body weights were recorded on Gestation Days 0, 4, 7, 11, 14, 17, and 20 and on Lactation Days 0 (when possible), 1, 4, 7, 10, 13, and 14.
Food Consumption
Food consumption was measured on a per cage basis on the corresponding weekly body weight days until pairing, but was not recorded during the breeding period. Once evidence of mating was observed, female food consumption was recorded on Gestation Days 0, 4, 7, 11, 14, 17, and 20 and on Lactation Days 1, 4, 7, 10, and 13.
Clinical Pathology
Blood samples for clinical pathology evaluations were collected from 5 animals/sex/group at the scheduled necropsies. The animals were fasted overnight prior to blood collection. Blood for serum chemistry and hematology was collected via the jugular vein for males and via the retro-orbital sinus following isoflurane anesthesia for females. Blood for coagulation parameters was collected from the vena cava at the time of necropsy. Blood was collected into tubes containing K2EDTA (hematology), sodium citrate (coagulation), or no anticoagulant (serum chemistry).
The following parameters were evaluated:
> Hematology and Coagulation:
Total leukocyte count (WBC)
Erythrocyte count (RBC)
Hemoglobin (HGB)
Hematocrit (HCT)
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin (MCH)
Mean corpuscular hemoglobin concentration (MCHC)
Platelet count (Platelet)
Prothrombin time (PT)
Activated partial thromboplastin time (APTT)
Reticulocyte count
Percent (RETIC)
Absolute (RETIC Absolute)
Differential leukocyte count -
Percent and absolute
-Neutrophil (NEU)
-Lymphocyte (LYMPH)
-Monocyte (MONO)
-Eosinophil (EOS)
-Basophil (BASO)
-Large unstained cell (LUC)
Red cell distribution width (RDW)
Hemoglobin distribution width (HDW)
Platelet estimate
Red cell morphology (RBC Morphology)
> Serum Chemistry:
Albumin
Total protein
Globulin [by calculation]
Albumin/globulin ratio (A/G Ratio) [by calculation]
Total bilirubin (Total BILI)
Urea nitrogen
Creatinine
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma glutamyltransferase (GGT)
Glucose
Total cholesterol (Cholesterol)
Calcium
Chloride
Phosphorus
Potassium
Sodium
Sorbitol dehydrogenase (SDH)
Triglycerides (Triglyceride)
Bile Acids
Appearance (Includes degree of hemolysis, lipemia, and icterus)
Parturition
All females were allowed to deliver naturally and rear their young to PND 13. During the period of expected parturition, the females were observed twice daily for initiation and completion of parturition and for signs of dystocia. On the day parturition was initiated (PND 0), pups were sexed and examined for gross malformations, and the numbers of stillborn and live pups were recorded. Individual gestation length was calculated using the date delivery started. - Oestrous cyclicity (parental animals):
- Vaginal lavages were performed daily and evaluated microscopically to determine the stage of the estrous cycle of each female for 14 days prior to randomization, continuing until evidence of copulation was observed. The average cycle length was calculated and reported for complete estrous cycles beginning with the first day of dose administration. Vaginal lavages were also performed on the day of necropsy to determine the stage of the estrous cycle.
- Sperm parameters (parental animals):
- The weight of the testis were examined. The testes with epididymides were collected, treated, fixed and stained for microcopic examination.
- Litter observations:
- Litter Reduction
To reduce variability among the litters, 8 pups/litter, 4 pups/sex when possible, were randomly selected on PND 4. Standardization of litter size was not performed on litters with fewer than 8 pups. Blood samples for possible future thyroid hormone analysis were collected from at least 2 culled pups/litter (pooled by litter) on PND 4; pups were euthanized by an intraperitoneal injection of sodium pentobarbital following blood collection and discarded. Remaining culled pups (not used for blood collection) were weighed, euthanized by an intraperitoneal injection of sodium pentobarbital on PND 4, and discarded.
Clinical Observations
Litters were examined daily for survival and any adverse changes in appearance or behavior. Each pup received a clinical examination on PND 1, 4, 7, 10, and 13. Any abnormalities in nesting and nursing behavior were recorded. The anogenital distance of all F1 pups was measured on PND 113; the absolute distance and the absolute distance relative to the cube root of body weight were reported for each pup.
Body Weights
Pups were individually weighed on PND 1, 4, 7, 10, and 13.
Sex Determination
Pups were individually sexed on PND 0, 4, and 13.
- Assessment of Areolas/Nipple Anlagen: On PND 13, all F1 male offspring were evaluated for the presence of thoracic nipples/areolae in accordance with previous established methods. The number of nipples was recorded if nipples were present, and a zero was recorded if nipples were absent. - Postmortem examinations (parental animals):
- Macroscopic Examination
A complete necropsy was conducted on all F0 parental animals at the scheduled termination. Blood samples were collected for thyroid hormone analysis immediately prior to euthanasia for males and on Lactation Day 13 for females. Uteri with no macroscopic evidence of implantation were opened and subsequently placed in 10% ammonium sulphide solution for detection of early implantation loss. Necropsy included examination of the external surface, all orifices, the cranial cavity, the external surface of the brain, and the thoracic, abdominal, and pelvic cavities, including viscera.
Organ Weights
The following organs were weighed from all F0 animals at the scheduled necropsies:
Adrenal glands
Brain
Epididymides (paired organs were weighed separately)
Heart
Kidneys
Liver
Ovaries with oviducts
Pituitary gland
Prostate gland
Seminal vesicles (with coagulating gland and fluid)
Spleen
Testes (paired organs were weighed separately)
Thymus gland
Thyroids with parathyroids
Histology and Microscopic Examinations
After fixation, specified tissues were trimmed, processed into paraffin blocks, sectioned, mounted on glass microscope slides, and stained with hematoxylin and eosin. PAS staining was used for the testes and epididymides. Microscopic examination was performed on all tissues from 5 animals/sex in the vehicle control and 1000 mg/kg/day groups at the scheduled necropsies. Gross lesions were examined from all animals in all groups. - Postmortem examinations (offspring):
- Each litter was examined daily for survival, and all deaths were recorded. Intact offspring that were found dead were necropsied via a dissection technique, which included examination of the heart and major vessels. Tissues were preserved in 10% neutral-buffered formalin for possible future histopathologic examination only as deemed necessary by the gross findings.
- Statistics:
- Data obtained from nongravid females were excluded from statistical analyses following the mating period. Where applicable, the litter was used as the experimental unit.
Analyses were conducted using two-tailed tests for minimum significance levels of 1% and 5%, comparing each test substance-treated group to the vehicle control group by sex. Parental mating, fertility, conception, and copulation indices were analyzed using the Chi-square test with Yates’ correction factor. Parental body weights (weekly, gestation, and lactation), body weight changes, and food consumption, offspring body weights and body weight changes, estrous cycle length, precoital intervals, gestation length, numbers of former implantation sites, and unaccounted-for sites, number of pups born, live litter size on PND 0, absolute and relative organ weights, clinical pathology values, thyroid hormone values, anogenital distance (absolute and relative to the cube root of body weight), number of nipples/areolae, and FOB data values were subjected to a parametric one-way ANOVA to determine intergroup differences. If the ANOVA revealed significant (p < 0.05) intergroup variance, Dunnett's test was used to compare the test substance-treated groups to the vehicle control group. FOB parameters that yield scalar or descriptive data in the test substance-treated groups were compared to the vehicle control group using Fisher’s Exact test. Mean litter proportions (percent per litter) of males at birth and postnatal survival were subjected to the Kruskal-Wallis nonparametric ANOVA to determine intergroup differences. If the nonparametric ANOVA revealed significant (p < 0.05) intergroup variance, Dunn’s test was used to compare the test substance-treated groups to the vehicle control group.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related clinical findings were noted at daily examinations following dose administration at any dosage level. Clinical findings, including hair loss, scabbing, and/or clear, red, or yellow material on various body surfaces, occurred infrequently, similarly in the vehicle control group, and/or in a manner that was not dose-related. No relationship to the test substance was evident.
- Mortality:
- no mortality observed
- Description (incidence):
- All F0 animals survived to the scheduled necropsies.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- - Males: Mean F0 body weights and body weight gains in the 100, 300, and 1000 mg/kg/day group males were unaffected by test substance administration throughout the study.
- Females: Mean F0 body weights and body weight gains in the 100, 300, and 1000 mg/kg/day group females were unaffected by test substance administration during the pre-mating period.
> Gestation: Mean F0 maternal body weights and body weight gains in the 100, 300, and 1000 mg/kg/day groups were unaffected by test substance administration during gestation. None of the differences from the vehicle control group were statistically significant.
> Lactation: Mean F0 maternal body weights and body weight gains in the 100, 300, and 1000 mg/kg/day groups were unaffected by test substance administration during lactation. None of the differences from the vehicle control group were statistically significant. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Mean F0 food consumption in the 100, 300, and 1000 mg/kg/day groups were unaffected by test substance administration throughout the study (males) and during the pre-mating period (females).
- Females
> Gestation: Mean F0 maternal food consumption in the 100, 300, and 1000 mg/kg/day groups was unaffected by test substance administration during gestation. None of the differences from the vehicle control group were statistically significant.
> Lactation: Mean F0 maternal food consumption in the 100, 300, and 1000 mg/kg/day groups was unaffected by test substance administration during lactation. None of the differences from the vehicle control group were statistically significant. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test substance-related effects on F0 hematology and coagulation. Significant (p < 0.05 or p < 0.01) differences from the vehicle control group were higher mean percentage of basophils noted in the 100 mg/kg/day group males, lower mean percentage of monocytes in the 300 mg/kg/day group females, and shorter mean prothrombin time in the 100 mg/kg/day group females. No dose-response relationship was evident. Therefore, these findings were considered incidental.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test substance-related effects on F0 serum chemistry parameters. Changes in serum chemistry consisted of lower mean cholesterol levels in the 1000 mg/kg/day group F0 males, higher mean albumin and total protein levels in the 1000 mg/kg/day group F0 females and higher mean A/G ratios in the 100 and 1000 mg/kg/day group F0 females. With the exception of the mean total protein level in the 1000 mg/kg/day group females, the differences from the vehicle control group were significant (p < 0.05). However, these changes did not correlate with other signs of toxicity or corresponding microscopic findings, and the magnitude of the changes were not toxicologically meaningful; therefore, the changes in serum chemistry were not considered test substance-related.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Home cage observations, handling observations, open field observations, sensory observations, neuromuscular and physiological observations and motor activity were all unaffected by test substance administration.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test substance-related histologic changes. Necrosis and inflammation of the arteries/arterioles (with thrombosis) in the submucosa of the cecum was observed in one 1000 mg/kg/day group female. This change was characterized by multifocal fibrinoid necrosis of the vessel wall with transmural infiltrates comprised of predominantly neutrophils and lymphocytes. In 1 vessel, a thrombus occludes the lumen. These changes were considered consistent with spontaneous necrotizing vasculitis (polyartertitis) that is occasionally observed in rodents and was not considered a test substance-related change. Minimal mononuclear infiltrates and minimal mineralization were observed in the 1000 mg/kg/day group female rats. These are well described background changes in the rat and were not considered test substance-related. Remaining histologic changes were considered to be incidental findings or related to some aspect of experimental manipulation other than administration of the test substance. There was no test substance-related alteration in the prevalence, severity, or histologic character of those incidental tissue alterations.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- Thyroid Hormone Analysis (F0 Males)
There were no test substance-related effects on serum T4 levels in the F0 males at any dosage level. Differences from the vehicle control group were considered to be the result of normal biological variation and were not considered to be of toxicological significance.
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- No test substance-related effects on reproductive performance were observed at any dosage level; the mean lengths of estrous cycles in treated groups were comparable to the vehicle control group.
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- No test substance-related effects on reproductive performance were observed at any dosage level. One male and female pair in the vehicle control group had evidence of mating but failed to produce a litter. The mean numbers of days between pairing and coitus in the test substance-treated groups were comparable to the vehicle control group value.
Effect levels (P0)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food consumption and compound intake
- haematology
- clinical biochemistry
- organ weights and organ / body weight ratios
- gross pathology
- neuropathology
- histopathology: non-neoplastic
- reproductive function (oestrous cycle)
- reproductive function (sperm measures)
- reproductive performance
Target system / organ toxicity (P0)
- Key result
- Critical effects observed:
- no
Results: F1 generation
Effect levels (F1)
- Key result
- Remarks on result:
- other: No data
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- No adverse effects were noted in F0 adults or F1 pups at any dosage level, therefore, 1000 mg/kg/day was considered to be the no-observed-adverse-effect level (NOAEL) for F0 reproductive and systemic toxicity and F1 neonatal toxicity of the test substance when administered orally by gavage to Crl:CD(SD) rats.
- Executive summary:
The potential toxic effects of the test substance at dosage levels of 100, 300 and 1000 mg/kg bw/day were investigated in an OECD 422 study, performed under GLP conditions. The test substance or vehicle control (corn oil) was administered to rats via gavage once daily to 4 groups of Crl:CD(SD) rats, each group consisting of 10 males and 10 females.
All F0 animals survived to the scheduled necropsy. No test substance-related clinical findings were noted at the daily examinations or approximately 1.5 hours following dose administration at any dosage level. No test substance-related effects on mean F0 male and female body weights, body weight gains, or food consumption (including during gestation and lactation in females) were noted at any dosage level. No test substance-related effects on F0 neurobehavioral parameters (FOB and motor activity) or reproductive performance (male and female mating and fertility, male copulation, and female conception indices, mean estrous cycle and gestation lengths, pre-coital intervals, and the process of parturition) were observed at 100, 300, or 1000 mg/kg/day.
There were no test substance-related effects on hematology, serum chemistry or thyroid hormone (T4) parameters in the F0 males and females at any dosage level. No test substance-related macroscopic or microscopic findings were noted at any dosage level. No test substance-related macroscopic or microscopic findings were noted at any dosage level. The mean numbers of former implantation sites and unaccounted-for sites were unaffected by test substance administration.
The mean numbers of F1 pups born, percentage of males at birth, live litter size on PND 0, postnatal survival, clinical condition of the pups, anogenital distance, areola/nipple retention (males), and mean pup body weights and body weight gains in the 100, 300, and 1000 mg/kg/day group were not affected by test substance administration to the F0 males and females. There were no test substance-related macroscopic findings noted in F1 pups that were found dead or at the scheduled necropsy on PND 13. There were no test substance-related effects on serum T4 levels in the F1 pups on PND 13 at any dosage level.
Under the conditions of this screening study, no adverse effects were noted in F0 adults or F1 pups at any dosage level. Therefore, 1000 mg/kg/day was considered to be the no-observed-adverse-effect level (NOAEL) for F0 reproductive and systemic toxicity and F1 neonatal toxicity of the test substance when administered orally by gavage to Crl:CD(SD) rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.